gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · BHCHealthcarePharmaceuticals

Bausch Health Companies Inc (BHC)

$8.34+2.46%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$8.34▲ 23.74% in range
Nov 4, 2025Low $4.43 · High $8.91Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Bausch Health Companies closed at $8.34 on Nov 4, up 2.46%, 6.4% below its 52-week closing high. Volume of 3.5M shares was 0.81× its 20-day average (close to normal).

Split-adjusted performance: +38.5% over one month, +47.6% over six months, +22.5% over one year.

In the quarter ended Sep 30, 2026, revenue was $2.94B, up 9.7% from a year earlier, with a net margin of 14.8%.

Short interest was 8.2M shares at the Oct 15 settlement, down 1.9% from the prior report (3.1% of float, 4.2 days to cover).

Market cap$3.12B374.3M shares
Revenue · quarter$2.94B+9.7% YoY
Diluted EPS$1.15+139.6% YoY
P/E · TTM—P/S 0.3×
Net margin14.8%Gross 75.0%
Dividend yieldNone$1 last paid
52-week range4.43 – 8.91−6.4% from high
Volume3.5M0.81× 20-day avg
Volatility · 60d67.8%Annualised
Short % of float3.1%4.2 days to cover
Net cash-$18.15BCash $2.48B
Next earnings—Not scheduled
Split-adjusted performance
1W +20.5%1M +38.5%3M +41.1%6M +47.6%YTD +20.0%1Y +22.5%3Y +24.7%5Y −70.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum93
Revenue growth55
Net margin83
Value (low P/E)—
Size85

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short8.2M−1.9% vs prior
Days to cover4.2Settled Oct 15
% of float3.1%
Short vol. 10d42.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BHCBausch Health Companies$8.34+2.46%+47.6%+9.7%14.8%—$3.12B
IDYAIDEAYA Biosciences$32.36+3.29%+12.6%−95.1%−1227.8%—$3.12BCompare
VRDNViridian Therapeutics$29.06+15.53%+65.7%+278.7%−39726.8%—$3.29BCompare
ELVNEnliven Therapeutics$47.25+5.40%+14.7%———$3.46BCompare
DYNDyne Therapeutics$18.54+2.71%−1.6%———$3.46BCompare
VKTXViking Therapeutics$27.97+7.21%−13.4%———$3.57BCompare
OGNOrganon &$13.83−0.14%+3.1%−1.7%10.4%17.1$3.63BCompare
AMLXAmylyx Pharmaceuticals$29.40+0.68%+83.1%———$3.69BCompare
IRONDisc Medicine$83.28+2.61%+21.3%———$3.70BCompare

News about Bausch Health Companies

All news →
BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan RisksZacks Investment Research · 18h ago▲ PositiveBHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesZacks Investment Research · 6d ago▲ PositiveBausch Health (BHC) Surpasses Q3 Earnings and Revenue EstimatesZacks Investment Research · Oct 28, 2026▲ PositiveBausch (BHC) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research · Oct 28, 2026▲ PositiveBHC Q3 Earnings Preview: Here's What You Should KnowZacks Investment Research · Oct 26, 2026Neutral

Quick answers

What does Bausch Health Companies do?
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb.
What is BHC's market cap?
$3.12B, based on the Nov 4 close of $8.34.
Does Bausch Health Companies pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BHC is sold short?
8.2M shares, 3.1% of float, as of Oct 15, 2026.
What sector is BHC in?
Healthcare, in the Pharmaceuticals industry.

About Bausch Health Companies

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

HQ: Quebec, A820,300 employeesListed Mar 31, 1994bauschhealth.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology